In the latest installment of The Wire’s Company in the News feature, we are looking at Hengrui Pharma, or Jiangsu Hengrui Medicine Company, one of China’s leading pharmaceutical firms driving research and production of innovative drugs. Hengrui’s chairman is famous for taking the company from a state-owned enterprise in 1970 to a $1.5 billion IPO in 2025, but perhaps even more so for his family: His wife is the billionaire founder and CEO of Jiangsu-based Hansoh Pharma, and his daughter is Hansoh’s Executive Director.
Click below to download the PDF.
Savannah Billman is a Staff Writer for The Wire China based in NYC. She previously worked at the National Committee on U.S.-China Relations.
